Answers are grounded in this paper and cite their sources.
BACKGROUND: The therapeutic efficacy of oncolytic vaccinia virus (JX-594) has been demonstrated in metastatic clear cell renal cell carcinoma (ccRCC); however, only selected patients respond, and there are no predictive biomarkers for therapeutic response. We aimed to identify predictive biomarkers for JX-594 treatment and elucidate the underlying mechanisms. METHODS: Four cell line-derived xenograft (CDX) models were developed using representative ccRCC cell lines harboring common mutations. Tumors were subcutaneously implanted into the right flank of BALB/c nude mice. Mice were treated with vehicle or JX-594 via intratumoral injection on days 0, 3, and 6, and tumor growth was evaluated. Therapeutic efficacies of JX-594 and a STING agonist were compared in the BAP1-mutant (769-P) CDX model. RESULTS: All four CDX models showed significant tumor shrinkage following JX-594 treatment versus control. JX-594 exhibited greater efficacy than the STING agonist in BAP1-deficient xenografts. The BAP1 mutation was associated with rapid tumor progression and a stronger response to JX-594. JX-594 induced IFN-β expression through IRF7-dependent signaling in BAP1-deficient cells, bypassing impaired STING-IRF3 signaling. CONCLUSIONS: We identified BAP1 as a potential predictive biomarker for JX-594 treatment and explored its underlying mechanisms. However, given that the study used immunodeficient models, the findings reflect tumor-intrinsic interferon responses and require further validation in immunocompetent models to assess immune microenvironment modulation and clinical relevance.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: